| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/28/2009 | US7524835 Tetrol steroids and esters |
| 04/28/2009 | US7524834 Antiinflammatory and antiallergic glucocorticosteroid, sterile glucocorticosteroids |
| 04/28/2009 | US7524833 Adsorbent silica gel-containing cartridges are loaded at the site of urine collection and effluent urine is left behind; fully loaded cartridges are collected and transported off-site for processing |
| 04/28/2009 | US7524832 Lyophile formulation of combretastatin A4 phosphate mono-tromethamine, wherein the pH is basified with sodium hydroxide or TRIS to prevent a pH drop during freezing; improved water solubility; rapidly regenerates combretastatin A-4 in vivo |
| 04/28/2009 | US7524831 Treatments for Flaviviridae virus infection |
| 04/28/2009 | US7524830 Decoy-containing pharmaceutical compositions and method of using the same |
| 04/28/2009 | US7524829 Specifically Ebola virus infections; antisense morpholino oligomer composed of morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit; target sequence within the AUG start site region |
| 04/28/2009 | US7524828 Immunostimulatory nucleic acid molecules |
| 04/28/2009 | US7524827 Two nucleotides containing 5-methylcytosine, the first hybridizing to the promoter region of a bcl-2 gene and the second hybridizing to a different type of oncogene; anticarcinogenic agents for melanomas, pancreatic, colon, breast, bladder, lung, leukemia, prostate, lymphoma, and ovarian cancers |
| 04/28/2009 | US7524826 Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque |
| 04/28/2009 | US7524825 Tricyclic-nucleoside compounds for treating viral infections |
| 04/28/2009 | US7524824 Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 04/28/2009 | US7524823 Ketolides having a fused five-membered lactone ring and a substituted cladinose sugar attached to the macrolide ring; erythromycin derivatives; improved activity towards bacteria resistant to erythromycin, clindamycin and tetracycline; antiinflammatory agents; phosphodiesterase inhibitors |
| 04/28/2009 | US7524822 Dissolving in a solvent, precipitating to form a suspension, isolating, desolventing; inhibitor of sodium-dependent glucose cotransporter, particularly SGLT2; metabolic disorders; improved bioavailability and shelf life |
| 04/28/2009 | US7524821 Scaffolded maleimide clusters for multivalent peptide assembly |
| 04/28/2009 | US7524817 Osteogenic protein/bone morphogenetic proteins of eukaryotic origin |
| 04/28/2009 | US7524812 A Omega-conopeptide, and the anitoxidant methionine, and either clonidine or baclofen; ziconotide retains its potency and is physically and chemically compatible with the analgesic; for intrathecal administration |
| 04/28/2009 | US7524675 Administering a polynucleotide encoding a Mycrobacterium kansasii-derived alpha antigen; asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis |
| 04/28/2009 | US7524674 Triple or double fusion vector harboring a Positron Emission Tomographic (PET), a bioluminescence and a fluorescence reporter gene that is imageable in living cells using a fluorescence microscope, a charge couple camera |
| 04/28/2009 | US7524643 Nucleotide sequences coding voltage gated calcium channels (VGCC) for treating neurological and cardiovascular disorders; anticonvulsant |
| 04/28/2009 | US7524530 Combining exendin and sucrose with oil phase comprising glycolic acid-lactic acid copolymer in methylene chloride to form emulsion, which is combined with coacervation agent (silicone oil) to form microparticles, transferring to quenching solvent, then hardening; sustained release; shelf life |
| 04/28/2009 | US7524517 Methods and compositions for P2X receptor calcium entry channels and other calcium entry mechanisms |
| 04/28/2009 | US7524514 Three dimensional, malleable cell culture; tissue engineering; pluripotent cells |
| 04/28/2009 | US7524512 Applying L-ascorbic acid in highly acidic concentration to middle ear |
| 04/28/2009 | US7524510 Alkyl-glycoside enhanced vaccination |
| 04/28/2009 | US7524484 Delivery of diphenhydramine through an inhalation route |
| 04/28/2009 | CA2562251C Pyrazolo'4,3-d pyrimidines |
| 04/28/2009 | CA2555258C 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity |
| 04/28/2009 | CA2525437C Benzamide inhibitors of the p2x7 receptor |
| 04/28/2009 | CA2510853C Pyrrolopyrimidine derivatives |
| 04/28/2009 | CA2507465C Phenyl substituted piperidine compounds for use as ppar activators |
| 04/28/2009 | CA2499330C New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| 04/28/2009 | CA2497171C Water stabilized medicinal aerosol formulation |
| 04/28/2009 | CA2496864C A pharmaceutical composition |
| 04/28/2009 | CA2472954C Aza-arylpiperazines |
| 04/28/2009 | CA2465336C Novel carbapenem compounds |
| 04/28/2009 | CA2450949C Methods and compositions for polyene antibiotics with reduced toxicity |
| 04/28/2009 | CA2446944C Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use |
| 04/28/2009 | CA2430734C Methods utilizing aryl thioimines in synthesis of erythromycin derivatives |
| 04/28/2009 | CA2425314C Pharmaceutical compositions containing oxapenem-3-carboxylic acids |
| 04/28/2009 | CA2418506C Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| 04/28/2009 | CA2416311C 16alpha-methyl or ethyl substituted estrogens |
| 04/28/2009 | CA2410220C 16, 17-carbocyclic condensed steroid compounds having selective estrogenic activity |
| 04/28/2009 | CA2408245C Media milling |
| 04/28/2009 | CA2400728C Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents |
| 04/28/2009 | CA2400176C Substituted piperazine compounds |
| 04/28/2009 | CA2380074C Novel amide derivatives |
| 04/28/2009 | CA2375259C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 04/28/2009 | CA2360236C Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| 04/28/2009 | CA2346396C 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 04/28/2009 | CA2344686C High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one |
| 04/28/2009 | CA2339765C Compounds and compositions for delivering active agents |
| 04/28/2009 | CA2336783C Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz[f]indoles, a method for the production thereof, and their use as medicaments |
| 04/28/2009 | CA2334761C Composition comprising .beta.-hydroxy-.beta.-methylbutyric acid and at least one amino acid and methods of use |
| 04/28/2009 | CA2278479C Carbohydrate mixture |
| 04/28/2009 | CA2273328C 5-cyclo indole compounds as 5-ht1d receptor ligands |
| 04/28/2009 | CA2259922C Calcium receptor active compounds |
| 04/28/2009 | CA2222964C Oxygen activatable formulations for disinfection or sterilization |
| 04/28/2009 | CA2220195C Therapeutic oligonucleotides targeting the human mdr1 and mrp genes |
| 04/28/2009 | CA2219988C Cd16-ii variants |
| 04/28/2009 | CA2212382C Cochleate delivery vehicles |
| 04/28/2009 | CA2197653C Delivery of nucleic acids |
| 04/28/2009 | CA2164838C A lotion comprising a tricyclic macrolide |
| 04/28/2009 | CA2155833C Photodynamic treatment of synovium |
| 04/23/2009 | WO2009052507A1 Bryostatin analogues, synthetic methods and uses |
| 04/23/2009 | WO2009052493A1 Time-controlled intraoral film former system for intraoral use |
| 04/23/2009 | WO2009052484A2 Predicting responsiveness to cancer therapeutics |
| 04/23/2009 | WO2009052440A1 Inhibitors of anti-apoptotic proteins |
| 04/23/2009 | WO2009052411A2 Methods for treatment of thiol-containing compound deficient conditions |
| 04/23/2009 | WO2009052379A2 Improved antitumoral treatments |
| 04/23/2009 | WO2009052377A1 Treatment of migraine headaches using antiestrogens |
| 04/23/2009 | WO2009052353A2 Trospium pharmaceutical formulations |
| 04/23/2009 | WO2009052350A1 Amine linked modulators of y-secretase |
| 04/23/2009 | WO2009052342A1 Combination therapy for reducing side effects using cannabinoid receptor ligands |
| 04/23/2009 | WO2009052334A1 Carbon linked modulators of y-secretase |
| 04/23/2009 | WO2009052310A1 A3 adenosine receptor antagonists |
| 04/23/2009 | WO2009052288A1 Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity |
| 04/23/2009 | WO2009052287A1 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors |
| 04/23/2009 | WO2009052264A2 Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| 04/23/2009 | WO2009052251A1 Pharmaceutical solid hybrids |
| 04/23/2009 | WO2009052237A1 Inhibitors of c-fms kinase |
| 04/23/2009 | WO2009052231A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052230A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052229A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052226A1 Crystalline indazole-derived chemotherepeutic |
| 04/23/2009 | WO2009052225A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052191A1 Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| 04/23/2009 | WO2009052180A1 Oral hygiene products containing ascorbic acid and method of using the same |
| 04/23/2009 | WO2009052145A1 Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| 04/23/2009 | WO2009052126A1 PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE |
| 04/23/2009 | WO2009052116A1 Methods for treating a variety of diseases and conditions, and compounds useful therefor |
| 04/23/2009 | WO2009052106A2 Formulation to improve gastrointestinal function |
| 04/23/2009 | WO2009052090A2 Silicate containing compositions and methods of treatment |
| 04/23/2009 | WO2009052079A1 Amide linked modulators of y-secretase |
| 04/23/2009 | WO2009052075A2 Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
| 04/23/2009 | WO2009052073A2 Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
| 04/23/2009 | WO2009052072A1 Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
| 04/23/2009 | WO2009052071A1 Treatment of sensorimotor disorders with 4- ( 1- ( 2, 3 -dimethylphenyl) ethyl) -1h-imidaz0le-2 ( 3h) -thione |
| 04/23/2009 | WO2009052068A1 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof |
| 04/23/2009 | WO2009052065A1 Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof |